We have collected information about Drug Delivery From Ocular Implants for you. Follow the links to find out details on Drug Delivery From Ocular Implants.
https://www.tandfonline.com/doi/abs/10.1517/17425247.3.2.261
Aug 12, 2014 · Drug delivery from ocular implants. Developing an intraocular drug delivery system (DDS) is urgently needed because most vitreoretinal diseases are refractory to conventional pharmacological approaches; eye drops and systemically administered drugs cannot deliver therapeutic drug concentrations into vitreoretinal tissue.Author: Tsutomu Yasukawa, Yuichiro Ogura, Hideya Kimura, Eiji Sakurai, Yasuhiko Tabata
https://www.ondrugdelivery.com/biodegradable-implants-sustained-intraocular-delivery-small-large-molecules/
Re-Vana Therapeutics is an ocular pharmaceuticals and drug delivery company focused on the development and commercialisation of long-acting biodegradable drug delivery platforms to treat chronic eye diseases. It is a spin-out company from the School of Pharmacy, Queens University Belfast.
https://www.researchgate.net/publication/7270728_Drug_delivery_from_ocular_implants
Conclusions Ultrasound application enhanced the delivery of an anti-inflammatory ocular drug, dexamethasone sodium phosphate, through the cornea in vivo. Ultrasound-enhanced ocular drug delivery...
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502010000300024
Intraocular implants are controlled drug delivery systems prepared from biodegradable or non-biodegradable polymers. Generally, these are introduced into the vitreous through an incision in the ocular pars plana, which is located posterior to the lens and anterior to the retina. Despite the invasive characteristics of the implantation technique, the implants present several advantages that outweigh the inconveniences of the implantation …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781321/
Sep 06, 2019 · Ocular drug transporters may alter drug’s efficacy and therefore, an evaluation of the interactions of new drug molecules and drug delivery systems with selected transporters is required during drug development . These ocular transporters can be divided into two major families: the solute carrier (SLC) family and the ATP-binding cassette (ABC) family.Author: Eliana B. Souto, João Dias-Ferreira, Ana López-Machado, Miren Ettcheto, Amanda Cano, Antonio Camins ...
https://www.sciencedirect.com/science/article/pii/S0169409X06001645
The initial intraocular implants were developed in order to achieve controlled and long standing drug delivery for cases of glaucoma filtering surgery failures, proliferative vitroretinopathy, CMV retinitis, endophtalmitis, and posterior capsule opacification.Author: J.L. Bourges, C. Bloquel, C. Bloquel, Aurélien Thomas, Aurélien Thomas, F. Froussart, F. Froussart, ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770064/
A major challenge in ocular drug delivery to the posterior segment is the multiple layers of protective blood-ocular barriers that limit drug access to intraocular tissues . As most vision impairing diseases are associated with the posterior eye segment, the administration of drug is becoming even more challenging [ 30 ].Author: Dharani Manickavasagam, Moses O. Oyewumi
https://www.aao.org/eyenet/article/promise-of-implantable-drug-delivery-systems
The implant’s helical coil increases the surface area for drug delivery and uses a polymer coating that’s commonly used for cardiac stents. “Theoretically, you can coat it with almost any drug you want,” said Dr. Dunn, who added that its design offers a lot of appeal.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289909/
Ocular barriers to transscleral drug delivery include: static barriers i.e., sclera, choroid and retinal pigment epithelium (RPE), and dynamic barriers, i.e., lymphatic flow in the conjunctiva and episclera, and the blood flow in conjunctiva and choroid [6,7].Author: Ashaben Patel, Kishore Cholkar, Vibhuti Agrahari, Ashim K Mitra
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306122/
Dec 26, 2010 · To overcome the above mentione d limitations, an increasing number of sustained-release drug delivery devices using different mechanisms and containing a variety of agents have been developed to treat uveitis. This article reviews major drug delivery technologies currently in clinical trials or at experimental stages for treatment of uveitis.Author: Nahid Haghjou, Masoud Soheilian, Mohammad Jafar Abdekhodaie
Searching for Drug Delivery From Ocular Implants?
You can just click the links above. The data is collected for you.
